vs
Apellis Pharmaceuticals, Inc.（APLS）与Root, Inc.（ROOT）财务数据对比。点击上方公司名可切换其他公司
Root, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的2.0倍（$397.0M vs $199.9M），Root, Inc.同比增速更快（21.5% vs -5.9%），过去两年Root, Inc.的营收复合增速更高（24.8% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Root Inc.旗下的Root保险公司是一家专注于汽车保险的线上保险公司，业务主要运营于美国地区，依托数字化技术为美国车主提供便捷的线上汽车保险服务。
APLS vs ROOT — 直观对比
营收规模更大
ROOT
是对方的2.0倍
$199.9M
营收增速更快
ROOT
高出27.5%
-5.9%
两年增速更快
ROOT
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $397.0M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 2.6% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | 21.5% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSROOT
| Q4 25 | $199.9M | $397.0M | ||
| Q3 25 | $458.6M | $387.8M | ||
| Q2 25 | $178.5M | $382.9M | ||
| Q1 25 | $166.8M | $349.4M | ||
| Q4 24 | $212.5M | $326.7M | ||
| Q3 24 | $196.8M | $305.7M | ||
| Q2 24 | $199.7M | $289.2M | ||
| Q1 24 | $172.3M | $254.9M |
净利润APLSROOT
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $-5.4M | ||
| Q2 25 | $-42.2M | $22.0M | ||
| Q1 25 | $-92.2M | $18.4M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $22.8M | ||
| Q2 24 | $-37.7M | $-7.8M | ||
| Q1 24 | $-66.4M | $-6.2M |
营业利润率APLSROOT
| Q4 25 | -25.6% | 2.6% | ||
| Q3 25 | 48.7% | 0.1% | ||
| Q2 25 | -18.6% | 7.1% | ||
| Q1 25 | -50.0% | 6.8% | ||
| Q4 24 | -12.3% | 10.7% | ||
| Q3 24 | -24.0% | 11.3% | ||
| Q2 24 | -14.7% | 1.3% | ||
| Q1 24 | -36.0% | 2.1% |
净利率APLSROOT
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | -1.4% | ||
| Q2 25 | -23.6% | 5.7% | ||
| Q1 25 | -55.3% | 5.3% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | 7.5% | ||
| Q2 24 | -18.9% | -2.7% | ||
| Q1 24 | -38.5% | -2.4% |
每股收益（稀释后）APLSROOT
| Q4 25 | $-0.40 | $0.35 | ||
| Q3 25 | $1.67 | $-0.35 | ||
| Q2 25 | $-0.33 | $1.29 | ||
| Q1 25 | $-0.74 | $1.07 | ||
| Q4 24 | $-0.30 | $1.42 | ||
| Q3 24 | $-0.46 | $1.35 | ||
| Q2 24 | $-0.30 | $-0.52 | ||
| Q1 24 | $-0.54 | $-0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $669.3M |
| 总债务越低越好 | — | $200.3M |
| 股东权益账面价值 | $370.1M | $284.3M |
| 总资产 | $1.1B | $1.7B |
| 负债/权益比越低杠杆越低 | — | 0.70× |
8季度趋势，按日历期对齐
现金及短期投资APLSROOT
| Q4 25 | $466.2M | $669.3M | ||
| Q3 25 | $479.2M | $653.3M | ||
| Q2 25 | $370.0M | $641.4M | ||
| Q1 25 | $358.4M | $609.4M | ||
| Q4 24 | $411.3M | $599.3M | ||
| Q3 24 | $396.9M | $674.8M | ||
| Q2 24 | $360.1M | $667.2M | ||
| Q1 24 | $325.9M | $640.5M |
总债务APLSROOT
| Q4 25 | — | $200.3M | ||
| Q3 25 | — | $200.4M | ||
| Q2 25 | — | $200.1M | ||
| Q1 25 | — | $200.0M | ||
| Q4 24 | — | $200.1M | ||
| Q3 24 | — | $300.9M | ||
| Q2 24 | — | $300.1M | ||
| Q1 24 | $93.1M | $299.3M |
股东权益APLSROOT
| Q4 25 | $370.1M | $284.3M | ||
| Q3 25 | $401.2M | $265.0M | ||
| Q2 25 | $156.3M | $244.5M | ||
| Q1 25 | $164.2M | $228.7M | ||
| Q4 24 | $228.5M | $203.7M | ||
| Q3 24 | $237.1M | $181.9M | ||
| Q2 24 | $264.3M | $151.3M | ||
| Q1 24 | $266.7M | $165.7M |
总资产APLSROOT
| Q4 25 | $1.1B | $1.7B | ||
| Q3 25 | $1.1B | $1.6B | ||
| Q2 25 | $821.4M | $1.6B | ||
| Q1 25 | $807.3M | $1.6B | ||
| Q4 24 | $885.1M | $1.5B | ||
| Q3 24 | $901.9M | $1.6B | ||
| Q2 24 | $904.5M | $1.5B | ||
| Q1 24 | $831.9M | $1.4B |
负债/权益比APLSROOT
| Q4 25 | — | 0.70× | ||
| Q3 25 | — | 0.76× | ||
| Q2 25 | — | 0.82× | ||
| Q1 25 | — | 0.87× | ||
| Q4 24 | — | 0.98× | ||
| Q3 24 | — | 1.65× | ||
| Q2 24 | — | 1.98× | ||
| Q1 24 | 0.35× | 1.81× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $206.5M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSROOT
| Q4 25 | $-14.2M | $206.5M | ||
| Q3 25 | $108.5M | $57.6M | ||
| Q2 25 | $4.4M | $52.0M | ||
| Q1 25 | $-53.4M | $26.8M | ||
| Q4 24 | $19.4M | $195.7M | ||
| Q3 24 | $34.1M | $49.4M | ||
| Q2 24 | $-8.3M | $62.6M | ||
| Q1 24 | $-133.0M | $14.5M |
自由现金流APLSROOT
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | $195.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | $62.4M | ||
| Q1 24 | $-133.3M | $14.3M |
自由现金流率APLSROOT
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | 59.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | 21.6% | ||
| Q1 24 | -77.3% | 5.6% |
资本支出强度APLSROOT
| Q4 25 | 0.1% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.1% | ||
| Q1 24 | 0.2% | 0.1% |
现金转化率APLSROOT
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 2.36× | ||
| Q1 25 | — | 1.46× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.17× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ROOT
暂无分部数据
